drugset / Trial / NCT00781911
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.
Timeline
- Start
- 2009-02
- Primary completion
- 2011-07
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cixutumumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | depot octreotide | Unknown | — | — |